Why Impurity Analysis Matters in Oligonucleotide Quality Control
In the quality control of chemically synthesized oligonucleotides, impurity analysis is a critical component for ensuring drug safety, efficacy, and consistent product quality. The industry has now reached a clear consensus on the classification of oligonucleotide impurities. In practice, these impurities are primarily categorized chemically according to their source and physicochemical properties, while their risk level is further ranked based on safety assessment.
Because some oligonucleotide impurities are highly similar to the active pharmaceutical ingredient (API) in both structure and physicochemical behavior, they can be difficult to separate and characterize. As a result, impurity testing often requires the combined use of orthogonal analytical techniques based on different separation mechanisms. Commonly applied methods include ion-pair reversed-phase high-performance liquid chromatography (IP-RP-HPLC), ion-exchange chromatography (IEX-HPLC), liquid chromatography-mass spectrometry (LC-MS), capillary electrophoresis (CE), size-exclusion chromatography (SEC), and hydrophilic interaction chromatography (HILIC). These platforms are typically paired with ultraviolet (UV) and mass spectrometry (MS) detectors for impurity assessment.
For stereoisomer analysis, suitable techniques may include chromatographic methods such as AEX-HPLC, IP-RP-HPLC, and HILIC, as well as ion mobility-mass spectrometry (IM-MS), capillary electrophoresis (CE), nuclear magnetic resonance (NMR), circular dichroism (CD), and enzyme cleavage-based analytical approaches.
Impurity studies are usually performed using impurity-enriched samples to support method development and validation. Typical materials include crude products before purification, samples prepared under different process parameters or purification conditions, forced degradation samples, and samples generated from stress and accelerated stability studies.
Sources of Oligonucleotide Impurities in Solid-Phase Synthesis
Solid-phase synthesis based on phosphoramidite chemistry is a multistep iterative process. For example, the synthesis of a 20-mer oligonucleotide may involve approximately 80 individual chemical reactions. Since no reaction proceeds with 100% efficiency, every step has the potential to generate impurities. In general, oligonucleotide-related impurities arise from three major sources: introduction from starting materials, formation during the manufacturing process, and degradation during production or storage.
Product-Related Impurities
Backbone Modification Impurities
Backbone modification impurities are associated with internucleotide linkages. These mainly include phosphorothioate (P=S)-related species, phosphate diester (P=O) impurities, and dithiophosphate impurities.
During the synthesis of phosphorothioate oligonucleotides, incomplete sulfurization or the use of sulfurizing reagents such as Beaucage reagent may result in the formation of phosphate diester linkages, generating phosphate diester impurities with a mass difference of -16 Da. Over-sulfurization, on the other hand, may lead to phosphorodithioate-related impurities. Such impurities can originate from starting materials or reagents, process conditions, or degradation pathways.
High-resolution mass spectrometry (HRMS) enables definitive identification through accurate mass measurement and is therefore considered a direct and confirmatory analytical tool. Chromatographic and electrophoretic methods are useful for in-process monitoring, but they generally do not provide sufficiently specific differentiation on their own. From a process control perspective, reagents, reaction time, and strictly anhydrous conditions should be optimized to ensure complete sulfurization.
Sequence Variant Impurities
Sequence variant impurities are species whose nucleotide length or sequence composition differs from that of the API. They can generally be classified into four categories: shortmers, longmers, base-substitution or base-loss impurities, and branched impurities.
Shortmer impurities are typically n-1 or n-2 species, meaning that one or more nucleotides are missing. They are mainly caused by incomplete detritylation, incomplete coupling, incomplete capping, or support-derived effects that interrupt chain extension or cause fragment loss. Longmer impurities are usually n+1 or n+2 species, containing one or more additional nucleotides. These arise from over-condensation or double-addition reactions during the coupling step.
Base-substitution or base-loss impurities may result from events such as cytosine deamination to uracil or hydrolytic depurination during acidic detritylation, particularly involving adenine residues, which can generate abasic sites. Branched impurities are typically formed when exocyclic amino protecting groups on nucleobases are lost, exposing reactive amino groups that subsequently react with phosphoramidites. This creates dual reactive sites that participate in chain elongation, ultimately producing branched structures with molecular weights close to twice that of the target product.
For detection and control, HRMS is widely used to confirm overall molecular weight, while MS-based sequencing or next-generation sequencing (NGS) may be applied for deeper characterization. IP-RP-HPLC is the core method for separating impurities with different lengths and sequences based on hydrophobicity differences, typically using ion-pairing reagents such as triethylamine and hexafluoroisopropanol. Anion-exchange chromatography (AEX) separates species based on charge differences and is especially effective for shortmer impurities. CE offers high separation efficiency and is useful for method validation. SEC separates molecules according to hydrodynamic volume and is particularly suitable for detecting high-molecular-weight impurities. Analytical ultracentrifugation (AUC) can be used for confirmation and quantification of aggregates.
Process control should follow a quality-by-design approach, with emphasis on optimizing coupling and capping steps, improving stepwise reaction efficiency, and monitoring dimethoxytrityl (DMT) release in real time. Preparative chromatography may be used to remove target impurities, while strict control is also required for bifunctional impurities in phosphoramidite monomers and for the efficiency of 5′-DMT deprotection.
Sugar or Base Modification Impurities
These impurities arise from modification of individual sugar moieties or nucleobase residues and often exist as mixtures of positional isomers. Sugar modification impurities include abasic sites, 2′-O-alkyl or 2′-O-alkoxyalkyl impurities such as 2′-O-methyl-related species, and sugar linkage isomers such as 2′,5′-linked structures. Base modification impurities include N-cyanoethyl thymine impurities, N-acetyl- or isobutyryl-diaminopurine impurities that may replace guanine, and oxidized bases such as 8-oxo-guanine.
HPLC-MS/MS can be used for structural identification of these impurities. In process control, the strength and duration of acidic deprotection and alkaline cleavage/deprotection steps should be optimized to minimize side reactions such as depurination. At the same time, monomer quality must be tightly controlled to reduce impurity formation.
High-Molecular-Weight Impurities
High-molecular-weight impurities are formed through intermolecular or intramolecular crosslinking of API molecules, generating dimers or more complex structures. Examples include pyrimidine dimers induced by UV exposure and base-sugar crosslinked products. SEC is the primary method for detecting aggregates and related high-molecular-weight species. During manufacturing, synthesis conditions should be optimized to prevent branching and crosslinking reactions.
Non-Oligonucleotide Product-Related Impurities Process-Related Impurities
Conventional oligonucleotide manufacturing processes typically include repeated washing during solid-phase synthesis, preparative purification, and ultrafiltration, which together provide strong clearance capability for small-molecule impurities. For organic solvents, reagents, small-molecule byproducts, residual solvents, elemental impurities, ligands, and protecting groups used during synthesis and production, residual risk should be assessed based on process clearance capability and actual analytical data, and then controlled in accordance with relevant regulatory guidelines.
Inorganic impurities mainly include residual catalytic metal ions such as palladium and copper, as well as salts such as triethylamine hydrochloride. These are generally controlled in line with ICH Q3D for elemental impurities. Residual solvents commonly include acetonitrile, dichloromethane, and N,N-dimethylformamide used during synthesis and purification, and are typically controlled according to ICH Q3C.
Residual starting materials, reagents, and intermediates may include unreacted nucleoside monomers such as phosphoramidites, activators such as tetrazole derivatives, capping reagents such as acetic anhydride, and oxidation or sulfurization reagents. Starting materials must be tightly controlled for critical reactive impurities. These impurities are chemically reactive, can participate in coupling reactions, and may become incorporated into the oligonucleotide chain. Because they are structurally very similar to the target product, they are difficult to remove during downstream purification. Typical examples include stereoisomers or regioisomers, multifunctional impurities, and reactive species with incomplete base protection. Since monomer impurities may be amplified throughout the synthesis process, very stringent quality specifications are required.
Process-derived impurities are non-target molecules generated during synthesis or post-synthesis processing, such as fragments released from the solid support and byproducts from protecting groups. Special attention should also be paid to mutagenic impurities, including nitrosamines. Risk assessment and control should consider nitrosamine impurities introduced through starting materials, as well as mutagenic byproducts arising from DMT removal reagents, ammonolysis reagents, temporary protecting group reactions in nucleoside phosphoramidites, and coupling-related process chemistry.
Other Impurities
Degradation Products
Degradation products are impurities generated during formulation, storage, or transportation under the influence of factors such as light, temperature, and pH. Many of the product-related impurities described above may also arise as degradation products.
Contaminants
Contaminants include microorganisms, endotoxins, and extraneous particulate matter. For injectable products, these are critical safety attributes and must be strictly controlled.
Analytical Strategies for Challenging Oligonucleotide Impurities
Given the structural complexity of oligonucleotide impurities and the high similarity between some impurities and the API, no single analytical technique is sufficient for comprehensive impurity characterization. Orthogonal strategies are therefore essential.
IP-RP-HPLC remains one of the most important tools for resolving sequence-related impurities. AEX provides excellent resolution for charge-dependent differences, particularly for shortmer species. LC-MS and HRMS are indispensable for molecular confirmation and structural elucidation. CE offers high-efficiency separation and method complementarity, while SEC is especially valuable for high-molecular-weight impurity and aggregate analysis. For stereochemical and conformational characterization, IM-MS, NMR, CD, and enzyme-based approaches can provide additional discriminatory power.
A robust impurity control strategy should integrate analytical characterization, process understanding, raw material control, purification capability, and stability evaluation to support product quality throughout development and manufacturing.
Related Biochemical Products or Technical Services for Promotion
Oligonucleotide Impurity Profiling and Characterization Services
Comprehensive impurity profiling services based on orthogonal platforms such as IP-RP-HPLC, AEX/IEX, LC-MS, HRMS, CE, SEC, and HILIC can support the identification, separation, and risk evaluation of sequence variants, backbone-modified impurities, sugar/base modification impurities, and high-molecular-weight species.
Method Development and Validation for Oligonucleotide Impurity Analysis
Custom analytical method development and validation services can help establish fit-for-purpose impurity control methods for release testing, in-process monitoring, stability studies, and comparability assessments. These services are particularly valuable when impurity species are highly similar to the API and require multiple orthogonal methods.
Forced Degradation and Stability Study Support
Forced degradation, stress testing, and accelerated stability study services can help reveal likely degradation pathways, enrich trace impurities, and support the development of stability-indicating methods for oligonucleotide APIs and drug products.
Raw Material and Phosphoramidite Quality Assessment
High-quality phosphoramidite monomers, sulfurization reagents, activators, capping reagents, and related raw material testing services can help reduce the introduction of reactive impurities at the source. Tight control of critical raw material quality is especially important for minimizing impurity amplification during multistep solid-phase synthesis.
Stereoisomer and Aggregate Characterization Solutions
Specialized analytical solutions for stereoisomer assessment and aggregate confirmation, including IM-MS, NMR, CD, SEC, and AUC-based studies, can provide deeper structural insight for complex oligonucleotide products and support advanced quality characterization.